Medivir and Boehringer Ingelheim entered into licensing agreement for Medivir’s antiviral drug, MIV-310 (alovudine) for treating multi-drug resistant HIV-1. Medivir focuses on the development of drugs that regulate the function of polymerases and proteases, both integral features of a plethora of diseases. This article features Medivir’s business strategies to produce a steady supply of candidate drugs for clinical development which it achieves through agreements with pharmaceutical corporations such as Boehringer and universities to assist its research projects.